Literature DB >> 16132481

Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.

Margherita Gavioli1, Gabriele Luppi, Lorena Losi, Federica Bertolini, Mario Santantonio, Anna Maria Falchi, Roberto D'Amico, Pier Franco Conte, Gianni Natalini.   

Abstract

PURPOSE: In advanced rectal cancer, chemoradiation can induce downstaging until complete disappearance of the tumor or its persistence in minimal form. The complete sterilized and the minimal residual disease often are considered similar. We evaluated the specific incidence of these two conditions and analyzed their impact in terms of local recurrence, distant metastasis, and survival.
METHODS: We studied 139 uT3/T4 N0/N+ rectal cancers, treated with preoperative chemoradiation and curative surgery after six to eight weeks. We evaluated ypTNM stage and tumoral regression, according to the five degrees proposed by Dworak, with special attention to 4 and 3 (sterilized and minimal residual disease).
RESULTS: Tumor downstaging occurred in 65 patients (46.7 percent), including 25 sterilized lesions (17.9 percent) and 24 minimal residual disease (17.2 percent). In median follow-up of 30 months, none of the patients with sterilized disease developed local or distant recurrence. Among patients with minimal residual disease, none developed local recurrence, whereas two (8.3 percent) developed distant metastasis, and one died from disease. In patients with gross residual disease (Grade 2, 1, 0) the percentage of local recurrence was 8.8 percent, distant recurrence 26.6 percent, and 13.3 percent died from disease. The difference between three groups is statistically significant as regards local and distant recurrence.
CONCLUSIONS: After preoperative therapy, the sterilized disease shows an excellent prognosis. The minimal residual disease has an important numeric incidence. Its outcome is different, with a not-negligible risk of distant recurrence. The minimal residual disease has a much better prognosis in comparison with the gross residual disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132481     DOI: 10.1007/s10350-005-0133-6

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  19 in total

Review 1.  [Pathological staging and response evaluation of rectal carcinoma].

Authors:  C Wittekind; B Oberschmid
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

Review 2.  Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.

Authors:  Takashi Akiyoshi; Takashi Kobunai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2012-06-16       Impact factor: 2.549

3.  Invited commentary on "Yun HR, Kim HC, Kim SH et al. (2010) Cytokeratin staining for complete remission in rectal cancer after chemoradiation. Int J Colorect Dis.

Authors:  Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2010-06-09       Impact factor: 2.571

4.  An international survey-based study on colorectal cancer pathology reporting-guidelines versus local practice.

Authors:  Maria Urbanowicz; Heike I Grabsch; Frederic Fiteni; Yan Liu; Carmela Caballero; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2018-09-26       Impact factor: 4.064

5.  Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer.

Authors:  Hirohiko Sato; Mitsuo Shimada; Nobuhiro Kurita; Takashi Iwata; Kozo Yoshikawa; Jun Higashigima; Motoya Chikakio; Hideya Kashihara; Chie Takasu; Noriko Matsumoto; Shozo Eto
Journal:  Int J Clin Oncol       Date:  2014-08-01       Impact factor: 3.402

6.  Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.

Authors:  Hong In Yoon; Woong Sub Koom; Yong Bae Kim; Byung Soh Min; Kang Young Lee; Nam Kyu Kim; Sang Joon Shin; Joong Bae Ahn; Ki Chang Keum
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-04       Impact factor: 4.553

7.  Human peripheral blood-derived mesenchymal stem cells with NTRK1 over-expression enhance repairing capability in a rat model of Parkinson's disease.

Authors:  Kun Liu; Wei Zhang; Yunlong Li; Qingfeng Ding; Yunan Bai; Fachen Wang; Guangming Xu
Journal:  Cytotechnology       Date:  2018-07-05       Impact factor: 2.058

8.  High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.

Authors:  M Kikuchi; T Mikami; T Sato; W Tokuyama; K Araki; M Watanabe; K Saigenji; I Okayasu
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

9.  Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  C Bengala; S Bettelli; F Bertolini; G Sartori; A Fontana; N Malavasi; R Depenni; S Zironi; C Del Giovane; G Luppi; P F Conte
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

10.  Clinical Significance of the Endoscopic Finding in Predicting Complete Tumor Response to Preoperative Chemoradiation Therapy in Rectal Cancer.

Authors:  Sun Gyo Lim; Young Bae Kim; Seung Yeop Oh
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.